The selling of a major stockholder has not changed Bintai's ability to fund (or not) NGIO's vaccine any more than the GNBT pps has affected the ability to create a viable Ii-Key vaccine. They bought the stock years before Covid-19 existed.

https://www.theedgemarkets.com/article/bintai...0.facebook

"Nusankota Development acquired the stake for RM10.01 million back in March 2017" @ .25 MYR/share

Share Prices
Dec. 7 = 1.39 MYR
Sold Dec. 16 @ .86 MYR
Today .66 MYR

After over 3 1/2 years of waiting and then seeing a downward slid from a high of 1.39, they wanted to make sure that they got some profit before it evaporated. Would any of us do something different in a situation like this. After all, this vaccine deal is something completely new for Bintai.

The need for a vaccine in Malaysia, hasn't changed, maybe gotten more intense, given what is being revealed since the mRNA rollout (supply chain issues, side effects, virus mutations, etc.).

I can’t help seeing GNBT/NGIO like an old fashion western, where the good guy keeps getting pummeled until the very end, when out of nowhere he rises up and saves the day. Anyway, I'm sticking around until they roll the credits.